Bundxcell

Bundxcell (Beijing) Biotechnology Co., Ltd. is an innovative company co-founded by a globally leading scientific and advisory team in the stem cell field, along with an operations team possessing extensive operational and management experience. The company focuses on drug development and clinical translation based on induced pluripotent stem cell (iPSC) technology. The team includes several top global stem cell research scientists, principal investigators of national key research projects, and returned overseas scientists. At the same time, a strong operations and investment team ensures continuous financing capabilities, allowing the company to invest continuously and stably in scientific research. Bundxcell concentrates on the clinical application of cell therapy using iPSC stem cell technology. It constructs clinical-grade, large-scale Chinese iPSC cell lines based on iPSC technology and develops various disease treatment products accordingly. The founding team has mastered globally leading technologies in iPSC cell line construction, directed differentiation of iPSC stem cells into multiple potentials, and large-scale stable culture of iPSC stem cells. Based on this technical foundation, the company further establishes cGMP-level cell production processes to achieve stable, uniform, and controllable production preparation of engineered iPSC stem cells for clinical research samples. The company focuses on stem cell therapeutic drugs for various degenerative diseases. Bundxcell will operate according to the development model of internationally leading innovative startups in the iPSC field, keeping pace with international frontiers, ultimately promoting the therapeutic application of stem cells, and helping to develop stem cell drugs for in vivo tissue and organ regeneration or cancer treatment. Bundxcell (Beijing) Biotechnology Co., Ltd. is committed to building a globally leading iPSC cell therapy drug development company in China.